(Post-pandemic Era)-Global Biological Drugs Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2016-2027

Report Code : XYZ2438564
Published On: Apr, 2021
Category : Medical Devices
Pages : 104

As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.

Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Research published a report for global Biological Drugs market in this environment.

In terms of revenue, this research report indicated that the global Biological Drugs market was valued at USD XXX million in 2020, and it is expected to reach a value of USD XXX million by 2027, at a CAGR of XX % over the forecast period 2021-2027. Correspondingly, the forecast analysis of Biological Drugs industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.

The Roche aims at producing XX K Units Biological Drugs in 2020, with XX % production to take place in global market, Amgen accounts for a volume share of XX %.

Regional Segmentation (Value; Revenue, USD Million, 2026-2027) of Biological Drugs Market Include by
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Biological Drugs Market
Roche
Amgen
Novo Nordisk
Abbott Laboratories
Pfizer
Novartis
Eli Lilly
Bristol-Myers Squibb
Biogen
Baxter

Major Type of Biological Drugs Covered in Research report:
Gardasil
Prenvar 13
Fluzone
Cervarix
Varivax
Application Segments Covered in Research Market
Auto-Immune Diseases
Blood Diseases
Cancer-Related Conditions
Diabetes
Cardiovascular Diseases

For any other requirements, please feel free to contact us and we will provide you customized report.
With tables and figures helping analyze worldwide (Post pandemic Era) Global Biological Drugs market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Global Biological Drugs Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate

1 Market Scope
1.1 Product Details and Introduction
1.1.1 Gardasil -Product Introduction and Major Manufacturers
1.1.2 Prenvar 13 -Product Introduction and Major Manufacturers
1.1.3 Fluzone -Product Introduction and Major Manufacturers
1.1.4 Cervarix -Product Introduction and Major Manufacturers
1.1.5 Varivax -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)

2 Global Biological Drugs Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2026-2027)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2026-2027)
2.3 Application Breakdown Estimates & Forecast, by Application (2026-2027)

3 Regional Market Analysis
3.1 China Biological Drugs Market
3.1.1 Top Companies leading Biological Drugs Development in China (2016-2021)
3.1.2 Sales Value of Major Company in China Market (2016-2021)
3.1.3 China Biological Drugs Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2026-2027)
3.2 EU Biological Drugs Market
3.2.1 Top Companies leading Biological Drugs Development in EU (2016-2021)
3.2.2 Sales Value of Major Company in EU Market (2016-2021)
3.2.3 EU Biological Drugs Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2026-2027)
3.3 USA Biological Drugs Market
3.3.1 Top Companies leading Biological Drugs Development in USA (2016-2021)
3.3.2 Sales Value of Major Company in USA Market (2016-2021)
3.3.3 USA Biological Drugs Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2026-2027)
3.4 Japan Biological Drugs Market
3.4.1 Top Companies leading Biological Drugs Development in Japan (2016-2021)
3.4.2 Sales Value of Major Company in Japan Market (2016-2021)
3.4.3 Japan Biological Drugs Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2026-2027)
3.5 India Biological Drugs Market
3.5.1 Top Companies leading Biological Drugs Development in India (2016-2021)
3.5.2 Sales Value of Major Company in India Market (2016-2021)
3.5.3 India Biological Drugs Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2026-2027)
3.6 Southeast Asia Biological Drugs Market
3.6.1 Top Companies leading Biological Drugs Development in Southeast Asia (2016-2021)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2016-2021)
3.6.3 Southeast Asia Biological Drugs Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2026-2027)
3.7 South America Biological Drugs Market
3.7.1 Top Companies leading Biological Drugs Development in South America (2016-2021)
3.7.2 Sales Value of Major Company in South America Market (2016-2021)
3.7.3 South America Biological Drugs Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2026-2027)

4 Value Chain (Impact of COVID-19)
4.1 Biological Drugs Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Biological Drugs Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors

5 Regional Market Forecast (2021-2027)
5.1 Global Biological Drugs Sales and Growth Rate (2021-2027)
5.2 Global Biological Drugs Sales Value and Growth Rate (2021-2027)

6 Biological Drugs Competitive Analysis
6.1 Roche
6.1.1 Roche Company Profiles
6.1.2 Roche Product Introduction
6.1.3 Roche Biological Drugs Production, Revenue (2016-2021)
6.1.4 SWOT Analysis
6.2 Amgen
6.2.1 Amgen Company Profiles
6.2.2 Amgen Product Introduction
6.2.3 Amgen Biological Drugs Production, Revenue (2016-2021)
6.2.4 SWOT Analysis
6.3 Novo Nordisk
6.3.1 Novo Nordisk Company Profiles
6.3.2 Novo Nordisk Product Introduction
6.3.3 Novo Nordisk Biological Drugs Production, Revenue (2016-2021)
6.3.4 SWOT Analysis
6.4 Abbott Laboratories
6.4.1 Abbott Laboratories Company Profiles
6.4.2 Abbott Laboratories Product Introduction
6.4.3 Abbott Laboratories Biological Drugs Production, Revenue (2016-2021)
6.4.4 SWOT Analysis
6.5 Pfizer
6.5.1 Pfizer Company Profiles
6.5.2 Pfizer Product Introduction
6.5.3 Pfizer Biological Drugs Production, Revenue (2016-2021)
6.5.4 SWOT Analysis
6.6 Novartis
6.6.1 Novartis Company Profiles
6.6.2 Novartis Product Introduction
6.6.3 Novartis Biological Drugs Production, Revenue (2016-2021)
6.6.4 SWOT Analysis
6.7 Eli Lilly
6.7.1 Eli Lilly Company Profiles
6.7.2 Eli Lilly Product Introduction
6.7.3 Eli Lilly Biological Drugs Production, Revenue (2016-2021)
6.7.4 SWOT Analysis
6.8 Bristol-Myers Squibb
6.8.1 Bristol-Myers Squibb Company Profiles
6.8.2 Bristol-Myers Squibb Product Introduction
6.8.3 Bristol-Myers Squibb Biological Drugs Production, Revenue (2016-2021)
6.8.4 SWOT Analysis
6.9 Biogen
6.9.1 Biogen Company Profiles
6.9.2 Biogen Product Introduction
6.9.3 Biogen Biological Drugs Production, Revenue (2016-2021)
6.9.4 SWOT Analysis
6.10 Baxter
6.10.1 Baxter Company Profiles
6.10.2 Baxter Product Introduction
6.10.3 Baxter Biological Drugs Production, Revenue (2016-2021)
6.10.4 SWOT Analysis

7 Conclusion
The (Post pandemic Era) Global Biological Drugs Market has been segregated into various crucial divisions including applications, types, and regions. Each market segment is intensively studied in the report contemplating its market acceptance, worthiness, demand, and growth prospects. The segmentation analysis will help the client to customize their marketing approach to have a better command of each segment and to identify the most prospective customer base.

Report Objectives / Segmentation Covered :

By Companies / players:
By Regions:
By Type:
By Application:

Frequently asked questions(FAQ's):

What trends are influencing the growth of the (Post pandemic Era) Global Biological Drugs Market?

New players are entering the (Post pandemic Era) Global Biological Drugs Market, while established companies are changing their business models and strategies. This pattern is likely to continue for the foreseeable future.

What are the major applications of the (Post pandemic Era) Global Biological Drugs Market?

Depending upon the type of applications, the (Post pandemic Era) Global Biological Drugs Market has been segmented into and other applications.

What is the forecasted growth rate of the (Post pandemic Era) Global Biological Drugs Market?

The (Post pandemic Era) Global Biological Drugs Market is expected to grow at a moderate CAGR during the forecast period of 2024 to 2029.

What trends may have an impact on the (Post pandemic Era) Global Biological Drugs Market's growth?

A handful of disruptive trends, nevertheless, will have a contradictory and significant impact on the development of the (Post pandemic Era) Global Biological Drugs Market as well as its distribution among its players

Who should consider the (Post pandemic Era) Global Biological Drugs Market study?

The (Post pandemic Era) Global Biological Drugs Industry stakeholders, executives, and experts, as well as individuals who need to develop consumer-friendly strategies and use technology to stay ahead of the competition.